Dr. Joseph Kozikowski will present on the hyperthermic enhancement of anticancer chemotherapeutics to clinical and research executives of global leader in oncology pharmaceuticals.

FRAMINGHAM, MA – May 2, 2001 – Clinivation, Inc. announced today that clinivation Founder and CEO Joseph Kozikowski, M.D. will present research findings to clinical and research executives of Eli Lilly Oncology.

As an authority on the development and commercialization of advanced medical technology, Dr. Kozikowski will review preclinical and clinical research in a presentation entitled “Delivering Thermally-Enhanced Anticancer Therapy” on May 7, 2001 in Pittsburgh, PA.

The presentation will review in vitro and in vivo preclinical research on the effects of hyperthermia on the anticancer activity of chemotherapeutics in the gemcitabine, doxorubicin, and other pharmaceutical classes.

The presentation will address Dr. Kozikowski’s translational research in hyperthermic anticancer therapy as Medical Director of ViaCirq, Inc. (Pittsburgh, PA).

About clinivation

Clinivation solutions deliver the digital advantage to outperform in new business environments with innovative and better ways to succeed in global development and commercialization.

Our cross‐functional software brings people and knowledge to the point of action to eliminate revenue traps, overcome process complexity, and enable execution with full visibility, decision support, and controls.

Resources

Customers

Clinivation solutions deliver the digital advantage to outperform in new business environments with innovative and better ways to succeed in global development and commercialization.

Our cross‐functional software brings people and knowledge to the point of action to eliminate revenue traps, overcome process complexity, and enable execution with full visibility, decision support, and controls.